Dr. Frederick Wilson + colleagues have identified RASGRF1/2 fusions across a variety of tumor types, gaining insight on incidence, structural diversity, + tissue distribution of this distinct fusion class. 🔗 www.nature.com/articles/s41... @tempusai.bsky.social

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing (@tempusai.bsky.social‬) https://cancerletter.com/drugs-and-targets/20250711_11a/

"This approach not only increases the likelihood of trial success, but also reduces the financial burden of conducting studies," write Eric Lefkofsky and Norman E. Sharpless cancerletter.com/trials-and-t...

Looking forward to seeing you at #ASCO25! Attend our Industry Expert Theater with Kate Sasser, PhD, Ezra Cohen, MD, and Halla Nimeiri, MD, to discover how we are redefining precision oncology at scale—where our tests fuel smarter decisions and data advances care. Find more info: tempus.co/3S7WDYp

We’re excited to announce a collaboration to develop a companion diagnostic test with Verastem Oncology. Our FDA-approved xT CDx assay is being leveraged as an investigational assay in Verastem’s global Phase 3 RAMP-301 clinical trial. Read more: tempus.co/3H3F9Kw

#NEWS: We are joining forces with @tempusai.bsky.social By combining our experimental data with Tempus AI's real-world data on its AI-powered platform, we aim to pave the way for novel cancer treatments. Learn more: bit.ly/43owlqa #DataScience #Cancer #ResearchCollaboration

At #MIGlobal, Kate Sasser, PhD, our Chief Scientific Officer, participated in the "Accelerating a Healthier Future Through AI" panel." @milkeninstitute.org Watch the full recording here: milkeninstitute.org/content-hub/...

We're on-site at #GU25! Stop by Booth #30 to meet with our team, learn more about our research in genitourinary cancers and explore our latest advancements in tech and #AI.

Tempus AI Introduced xH: Its First Whole-Genome Sequencing Test oncodaily.com/insight/temp... #AML #AI #Cancer #MyelodysplasticSyndromes #MDS #Medicine #MyeloproliferativeNeoplasms #OncoDaily #Oncology #Health